Back to News
Market Impact: 0.3
GENFIT To Advance Nangibotide Into Phase 2 Trial For Acute-On-Chronic Liver Failure
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
GENFIT plans to advance nangibotide into a Phase 2 proof-of-concept trial for Acute-on-Chronic Liver Failure, a rare and life-threatening liver condition. The clinical-development milestone is a modest positive catalyst for the company, though efficacy, safety and commercialization remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
GNFT0.55
More News
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Reliance Worldwide shares hit 1-year high on Brookfield’s $2.9 bln deal
- Why Dave & Buster's Stock Tumbled Today